Predictability of B cell clonal persistence and immunosurveillance in breast cancer.
Published version
Peer-reviewed
Repository URI
Repository DOI
Type
Change log
Authors
Abstract
B cells and T cells are important components of the adaptive immune system and mediate anticancer immunity. The T cell landscape in cancer is well characterized, but the contribution of B cells to anticancer immunosurveillance is less well explored. Here we show an integrative analysis of the B cell and T cell receptor repertoire from individuals with metastatic breast cancer and individuals with early breast cancer during neoadjuvant therapy. Using immune receptor, RNA and whole-exome sequencing, we show that both B cell and T cell responses seem to coevolve with the metastatic cancer genomes and mirror tumor mutational and neoantigen architecture. B cell clones associated with metastatic immunosurveillance and temporal persistence were more expanded and distinct from site-specific clones. B cell clonal immunosurveillance and temporal persistence are predictable from the clonal structure, with higher-centrality B cell antigen receptors more likely to be detected across multiple metastases or across time. This predictability was generalizable across other immune-mediated disorders. This work lays a foundation for prioritizing antibody sequences for therapeutic targeting in cancer.
Description
Acknowledgements: The authors thank the late Nir Friedman at the Weizmann Institute for the many scientific discussions that contributed to the central idea that rooted this work. S-J.S. was supported by a Whitney Wood Scholarship awarded by the Royal College of Physicians (United Kingdom). C.C. was supported by funding from CRUK (grant numbers A17197, A27657 and A29580), an NIHR Senior Investigator Award (grant number NF-SI-0515-10090), and a European Research Council Advanced Award (grant number 694620). R.J.M.B.-R. was supported by the Wellcome Trust and University of Oxford. O.M.R. was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) and the Medical Research Council (UK; MC_UU_00002/16). B.S. is supported by an NIHR Academic Clinical Lectureship (CL-2021-13-002), Academy of Medical Sciences (SGL028\1074) and The British Medical Association Vera Down Award. We thank Breast Cancer Now for funding this work as part of Programme Funding to the Breast Cancer Now Toby Robins Research Centre. We thank the Asociación Española contra el Cáncer, Cellex foundation, and the clinical team at the Breast Cancer Unit of Vall d’Hebron University Hospital/Institute of Oncology and the Cambridge Breast Cancer Research Unit for facilitating the collection and processing of biological samples. We are very grateful for the generosity of all the participants that donated samples for analysis.
Funder: Wellcome Trust (Wellcome); doi: https://doi.org/10.13039/100004440
Funder: University of Oxford (Oxford University); doi: https://doi.org/10.13039/501100000769
Funder: The British Medical Association Vera Down Award
Journal Title
Conference Name
Journal ISSN
1529-2916
Volume Title
Publisher
Publisher DOI
Rights and licensing
Sponsorship
Cancer Research UK (A27657)
National Institute for Health and Care Research (IS-BRC-1215-20014)